Literature DB >> 24655550

SPAK mediates KCC3-enhanced cervical cancer tumorigenesis.

Min-Hsi Chiu1, Hsiao-Sheng Liu, Yi-Hui Wu, Meng-Ru Shen, Cheng-Yang Chou.   

Abstract

Ste20-related proline/alanine-rich kinase (SPAK) plays a role in regulating many biological activities, and interacts with K-Cl co-transporter 3 (KCC3); however, the importance of SPAK for KCC3 function has not been demonstrated. Here, we investigated the role of SPAK in KCC3-regulated cell invasiveness and tumor formation. We show that induction of KCC3 expression triggers activation of the NF-κB and SPAK signaling cascades, leading to activation of p38 mitogen-activated protein kinase (MAPK) and matrix metalloproteinase-2 (MMP2). A small interference RNA-mediated reduction in SPAK protein levels suppressed the invasive ability and oncogenic potential of cervical cancer cells, and decreased tumor formation in mouse xenografts. A combination of experimental approaches, including RT-PCR and real-time RT-PCR, gelatin zymography, NF-κB luciferase activity and chromatin immunoprecipitation assays, showed that the induction of KCC3 over-expression increased MMP2 expression and augmented binding of NF-κB to its putative SPAK promoter binding site, suggesting that the SPAK/MMP2 axis is up-regulated by NF-κB. Pharmacological inhibition of NF-κB or MMP2 abrogated KCC3-triggered, SPAK-dependent cell invasiveness. Furthermore, p38 MAPK was identified as the upstream regulator of KCC3-dependent MMP2 activation. We conclude that SPAK may promote KCC3-mediated tumor aggressiveness via the NF-κB/p38 MAPK/MMP2 axis.
© 2014 FEBS.

Entities:  

Keywords:  KCC3; NF-κB; Ste20-related proline/alanine-rich kinase; matrix metalloproteinase; tumor aggressiveness

Mesh:

Substances:

Year:  2014        PMID: 24655550     DOI: 10.1111/febs.12787

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  7 in total

1.  Identification of novel biomarkers differentially expressed between African-American and Caucasian-American prostate cancer patients.

Authors:  Fei Ye; Xiaoxia Han; Yonzhao Shao; Jingzhi Lo; Fengxia Zhang; Jinhua Wang; Jonathan Melamed; Fang-Ming Deng; Karen S Sfanos; Angelo De Marzo; Guoping Ren; Dongwen Wang; David Zhang; Peng Lee
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

Review 2.  WNK pathways in cancer signaling networks.

Authors:  Sachith Gallolu Kankanamalage; Aroon S Karra; Melanie H Cobb
Journal:  Cell Commun Signal       Date:  2018-11-03       Impact factor: 5.712

Review 3.  The Important Role of Ion Transport System in Cervical Cancer.

Authors:  Yih-Fung Chen; Meng-Ru Shen
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

4.  Knockdown of STK39 suppressed cell proliferation, migration, and invasion in hepatocellular carcinoma by repressing the phosphorylation of mitogen-activated protein kinase p38.

Authors:  Jian Chen; Luke Zhou; Jie Yang; Hui Xie; Lin Liu; Youwei Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  CircPTK2 Suppresses the Progression of Gastric Cancer by Targeting the MiR-196a-3p/AATK Axis.

Authors:  Ling Gao; Tingting Xia; Mingde Qin; Xiaofeng Xue; Linhua Jiang; Xinguo Zhu
Journal:  Front Oncol       Date:  2021-09-15       Impact factor: 6.244

6.  Phosphorylated WNK kinase networks in recoded bacteria recapitulate physiological function.

Authors:  Paula Schiapparelli; Natasha L Pirman; Kyle Mohler; Pierre A Miranda-Herrera; Natanael Zarco; Onur Kilic; Chad Miller; Sagar R Shah; Svetlana Rogulina; William Hungerford; Laura Abriola; Denton Hoyer; Benjamin E Turk; Hugo Guerrero-Cázares; Farren J Isaacs; Alfredo Quiñones-Hinojosa; Andre Levchenko; Jesse Rinehart
Journal:  Cell Rep       Date:  2021-07-20       Impact factor: 9.423

7.  STK39 promotes breast cancer invasion and metastasis by increasing SNAI1 activity upon phosphorylation.

Authors:  Zhaoping Qiu; Bo Dong; Weijie Guo; Rychahou Piotr; Greg Longmore; Xiuwei Yang; Zhiyong Yu; Jiong Deng; B Mark Evers; Yadi Wu
Journal:  Theranostics       Date:  2021-06-11       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.